Core Viewpoint - The newly listed company Insilico Medicine (03696.HK) has announced a long-term R&D collaboration with the French pharmaceutical company Servier, valued at up to $888 million, marking the first business development (BD) deal in the biopharmaceutical sector since 2026 [1][4]. Group 1: Collaboration Details - The collaboration with Servier will leverage Insilico's AI platform Pharma.AI, focusing on challenging targets in oncology to identify and develop new therapeutic drugs [4]. - Insilico is eligible for an upfront payment of up to $32 million and milestone payments based on R&D progress, while Servier will lead clinical validation and commercialization [5][4]. - Insilico has previously established partnerships with companies like Fosun Pharma, Sanofi, and Eli Lilly, with four oncology projects already licensed to partners [6]. Group 2: Financial Performance - Insilico's revenue primarily comes from licensing agreements, with projected revenues of approximately $30.15 million, $51.18 million, $85.83 million, and $27.46 million for the years 2022 to 2025 [6]. - The company reported losses of $222 million, $212 million, $17.1 million, and $19.2 million for the years 2022 to 2025, although losses are gradually narrowing [10]. - The IPO raised a total of HKD 2.277 billion, making it the highest fundraising biopharmaceutical IPO in Hong Kong for 2025, with a stock price increase of 55.43% within four trading days [8]. Group 3: Market Context and Future Outlook - The AI pharmaceutical sector is still in its early commercialization phase, requiring extensive clinical trials for validation [1][8]. - Insilico aims to balance high R&D investments with revenue generation through strategic partnerships, enhancing its long-term competitiveness while creating stable cash flow [11]. - The overall sentiment in the market regarding AI pharmaceuticals is mixed, with some investors optimistic about future growth while others express concerns over the unclear development pathways [9].

Core Insights - Insilico Medicine has entered a multi-year R&D collaboration with global pharmaceutical company Sihuiya, with a total agreement amount of up to $888 million [1] - The collaboration will leverage Insilico's AI platform Pharma.AI to develop challenging targets in the oncology field, with Insilico receiving up to $32 million in upfront and milestone payments [1] - Pharma.AI is a leading generative AI-driven drug discovery and development system that significantly enhances early-stage drug development efficiency, reducing the time from target discovery to preclinical candidate confirmation to 12-18 months compared to the traditional average of 4.5 years [1] Company Performance - Insilico has developed over 20 clinical/IND stage assets based on Pharma.AI, covering areas such as oncology, immunology, fibrosis, and metabolism [2] - The core self-developed product ISM001-055 for idiopathic pulmonary fibrosis has entered Phase II clinical trials, making it the fastest progressing AI drug globally [2] - Revenue from drug discovery and pipeline development is projected to be $28.648 million, $47.818 million, and $79.733 million from 2022 to 2024, accounting for over 90% of total revenue, while software sales remain below 10% [2] Financial Overview - Insilico's revenue from 2022 to the first half of 2025 is approximately $30.147 million, $51.180 million, $85.834 million, and $27.456 million, respectively [3] - Adjusted net losses during the same period were $70.804 million, $67.361 million, $22.665 million, and $15.409 million [3]

如此也意味着，在资本市场的喧嚣背后，全球制药行业正以复杂的心态拥抱AI。一方面，AI在提升早 期药物发现效率方面展现出诱人潜力；另一方面，整个AI制药产业仍处于商业化早期，绝大多数公司 尚未实现盈利，其最终价值需通过漫长且高风险的临床试验来验证。不难发现，英矽智能的案例，恰好 为观察这一矛盾中的产业提供了一个绝佳的切片。 战略互补 对于医药产业而言，此次交易受到关注的一大原因在于，英矽智能与施维雅聚焦于"具有挑战性的靶 点"。 一方面，对施维雅而言，这是一次以可控成本获取前沿探索能力的"外包"式创新。传统药企面对难成药 靶点，常因内部研发投入产出比不确定而却步。通过与AI平台合作，施维雅将前期探索的高风险和不 确定性部分转移，以首付款和里程碑付款为杠杆，撬动AI的计算能力，自身则聚焦于擅长的临床开发 与商业化。这是一种风险分散、效率优化的策略，而非根本性的自我颠覆。 另一方面，对英矽智能来说，此次合作的核心价值在于"平台验证"与"现金流补充"。获得跨国药企的背 书，可显著提升其Pharma.AI平台的市场信誉度。高达 3200 万美元的首付款及近期研发里程碑付款，为 公司提供了宝贵的研发资金。这种"服务换现金 ...

中国AI Biotech第一股，来了！ 12月30日，英矽智能正式登陆港股，成为中国首家以生成式人工智能驱动药物研发为核心业务的上市公司，首日高开45%。 这一天，距离英矽智能成立已经过去将近12年的时间，历经行业多轮周期。公司不仅经受住了种种考验，更成长为全球AI制药领域最具代表性的企业之 一。 如今，恰逢生成式AI掀起新一轮技术革命，叠加中国创新药海外BD热潮，作为全球极少数同时具备生成式AI平台、拥有临床阶段管线，并成功达成多笔 高价值对外授权交易的AI Biotech，英矽智能的稀缺价值进一步凸显，值得更多期待。 公司自主研发的核心引擎Pharma.AI平台覆盖从靶点识别、小分子生成、先导化合物优化到临床试验预测的端到端药物研发链条，将候选药物从靶点发现 到临床前候选药物（PCC）确认的时间从传统方法的4.5年缩短至12至18个月。 依托Pharma.AI平台，英矽智能已自主开发出超过20项处于临床或IND申报阶段的创新资产，涵盖纤维化、肿瘤学、免疫学、代谢、抗疼痛等领域，充分 验证了其AI技术在真实药物开发场景中的转化能力。 与此同时，公司已将三项高潜力候选药物授权给国际知名企业，累计最高合约总价值 ...

Core Insights - Insilico Medicine announced a research collaboration with Servier worth a total of $888 million, combining Insilico's AI-driven drug development platform with Servier's global expertise in oncology drug development [1] Group 1: Collaboration Details - The agreement allows Insilico to receive up to $32 million in upfront and near-term milestone payments [1] - Insilico will utilize its proprietary AI technology platform to identify and advance potential drug candidates that meet established drug development and scientific standards [1] - Servier will co-fund the research costs and will lead subsequent clinical validation, regulatory communication, and commercialization of promising oncology drug candidates globally after nomination [1]

英矽智能创始人、首席执行官兼首席商务官Alex Zhavoronkov博士表示："随着我们将生成式人工智能 更深入地融入药物研发的各个阶段，我相信制药超级智能的未来近在眼前，即AI智能体能够真正做出 决策并设计实验，形成推动药物研发更快、更智能、更安全的良性循环。" 英矽智能在人工智能驱动的肿瘤药物研发方面已建立起覆盖多种癌症适应症、兼具中度新颖机制与成熟 机制的肿瘤管线。其中，具有潜力成为同类最佳(best-in-class)疗法的泛TEAD抑制剂ISM6331以及 MAT2A抑制剂ISM3412，均已启动全球多中心I期临床试验。此外，公司还有四个肿瘤项目已全部或部 分对外授权给合作伙伴，相关I期临床试验正在稳步推进。 港股"AI制药第一股"英矽智能1月5日宣布，已与全球独立制药公司施维雅(Servier)达成了一项总金额达 8.88亿美元的研发合作。该合作将英矽智能人工智能驱动的药物研发平台与施维雅在抗肿瘤药物研发领 域的全球专业优势相结合，聚焦于创新抗肿瘤疗法的发现与开发。 根据协议，英矽智能将有资格获得最高3200万美元的首付款及近期研发里程碑付款，并将主导利用其人 工智能技术平台，发现并开发符合既定 ...

Core Viewpoint - The collaboration between Insilico Medicine and a global independent pharmaceutical company, Sivea, is valued at up to $888 million, focusing on the development of new cancer therapies using Insilico's AI platform, Pharma.AI [1] Group 1: Partnership Details - Insilico Medicine has entered into a multi-year research collaboration with Sivea, managed by a foundation [1] - The agreement allows Insilico to receive up to $32 million in upfront and near-term milestone payments [1] - Insilico will lead the discovery and development of potential drug candidates using its AI technology, while Sivea will share R&D costs and oversee clinical validation and commercialization [1] Group 2: Financial Implications - The total value of the collaboration is projected to reach $888 million, indicating significant financial potential for both companies [1] - The initial payment structure includes a maximum of $32 million, which could provide immediate funding for Insilico's research efforts [1] Group 3: Focus Area - The partnership will concentrate on challenging targets in the oncology field, aiming to identify and develop novel therapeutic drugs [1] - The use of the Pharma.AI platform is expected to enhance the efficiency and effectiveness of drug discovery processes [1]

Core Insights - The collaboration between Insilico Medicine and Servier, valued at $888 million, marks a significant advancement in the AI drug development sector, focusing on challenging oncology targets and innovative therapies [1] - This partnership highlights the transition of AI in pharmaceuticals from concept validation to a new cycle of value realization, emphasizing the potential of Insilico's Pharma.AI platform [1] Financial Aspects - Insilico Medicine is eligible for an upfront payment of up to $32 million and milestone payments as part of the agreement [1] - The collaboration is seen as a key milestone following Insilico's successful IPO, which was characterized by an oversubscription of 1,427 times in the public offering, raising over HKD 32.83 billion [3] Strategic Partnerships - Insilico has established a broad global network since 2020, forming numerous AI-driven research collaborations and pipeline licenses, including partnerships with major pharmaceutical companies like Sanofi and Eli Lilly [4][5] - The collaboration with Servier is expected to leverage Insilico's AI capabilities and Servier's global commercialization strengths, creating synergistic value [2] Market Performance - Insilico's stock has shown strong performance post-IPO, reflecting market optimism regarding the "AI + biopharma" landscape [3] - The involvement of top-tier investors such as Eli Lilly, Tencent, and Temasek indicates strong capital backing and confidence in the AI drug development sector [3] Future Outlook - The partnership and financial achievements signal a shift in the industry towards deeper commercialization of AI technologies in drug development, with a focus on clinical trial success rates as the ultimate measure of efficacy [6] - The ongoing challenge for Insilico will be to validate the effectiveness of AI-driven drug candidates in clinical settings, moving from early-stage development to therapeutic validation [6]

Core Insights - The collaboration between Insilico Medicine and Servier, valued at $888 million, marks a significant advancement in the AI-driven pharmaceutical sector, focusing on challenging oncology targets and innovative therapies [1][2] - This partnership highlights the transition of AI in drug development from concept validation to a new cycle of value realization, emphasizing the potential of Insilico's Pharma.AI platform [1][6] Group 1: Partnership Details - The agreement allows Insilico to receive up to $32 million in upfront and milestone payments, leveraging its AI technology to identify and advance drug candidates [1] - Servier will share the R&D costs and lead the clinical validation and commercialization of promising drug candidates globally [1] Group 2: Market Performance - Insilico Medicine's IPO on December 30, 2025, was highly successful, with a subscription rate of approximately 1427 times for the public offering, raising over HKD 328.3 billion [3] - The strong backing from top-tier investors, including Eli Lilly, Tencent, and Temasek, reflects a high consensus on the AI pharmaceutical sector's potential [3] Group 3: Strategic Collaborations - Since 2020, Insilico has established a vast network of global partnerships, achieving multiple AI-driven R&D collaborations and pipeline licenses, with total potential values reaching up to $2.1 billion [4] - Collaborations with major pharmaceutical companies like Sanofi and Eli Lilly further enhance Insilico's capabilities in drug development [4] Group 4: Future Challenges - Despite the promising developments, the true test for AI in drug development will be the clinical trial success rates, as the industry shifts focus from early-stage research to efficacy validation [6] - The upcoming years will be crucial in determining whether AI can effectively disrupt traditional drug development timelines and success rates [6]

Core Viewpoint - The collaboration between 英硅智能 (03696.HK) and a global independent pharmaceutical company,施维雅, is valued at up to $888 million, focusing on the development of new cancer therapies using the company's AI platform, Pharma.AI [1] Group 1: Collaboration Details - The partnership is a multi-year research collaboration aimed at identifying and developing new therapeutic drugs targeting challenging oncology areas [1] - The agreement allows the company to receive up to $32 million in upfront and milestone payments for research [1] - The company will lead the discovery and development of potential drug candidates using its AI technology platform, while 施维雅 will share the R&D costs and lead subsequent clinical validation and commercialization processes [1]